Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Inotuzumab ozogamicin

EU orphan designation number: EU/3/13/1127   
Active ingredient: Inotuzumab ozogamicin
Indication: Treatment of B-cell acute lymphoblastic leukaemia
Sponsor: Pfizer Limited
Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
11/06/2013 Centralised Orphan - Designation EMA/OD/194/12 (2013)3663 of 07/06/2013